Kantonsspital St.Gallen
login

publications

Ludwig Plasswilm

title  
 
Ghadjar P, Hayoz S, Bernhard J, Zwahlen D R, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A C, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D G, Khanfir K, Gomez S, Wust P, Thalmann G N, Aebersold D M, Swiss Group For Clinical Cancer Research (SAKK) . Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol 2021; 80:306-315.
   
Vue E, Pratsinis M, Plasswilm L, Schmid H P, Panje C, Betschart P. Radiotherapy or surgery ? Comparative, qualitative assessment of online patient education materials on prostate cancer. Curr Oncol 2021; 28:3420-9.
   
Vu E, Pratsinis M, Plasswilm L, Schmid H P, Panje C, Betschart P. Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer. Curr Oncol 2021; 28:3420-3429.
   
Iseli T, Fischer G, Panje C, Glatzer M, Hundsberger T, Rothermundt C, Schmidt B, Sirén C, Plasswilm L, Putora P M. Insular Decision Criteria in Clinical Practice: Analysis of Decision-Making in Oncology. Oncology 2020; 98:438-444.
   
Viktorin-Baier P, Putora P M, Schmid H P, Plasswilm L, Schwab C, Thoeni A, Hochreiter W, Prikler L, Suter S, Stucki P, Müntener M, Blick N, Schiefer H, Guesewell S, Zürn K, Engeler D S. Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU Int 2020; 125:827-835.
   
Panje C, Lupatsch J E, Barbier M, Pardo E, Lorez M, Dedes K J, Aebersold D M, Plasswilm L, Gautschi O, Schwenkglenks M, Swiss Group For Clinical Cancer Research (SAKK) . A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol 2020; 31:501-506.
   
Hendrickx A, Cozzio A, Plasswilm L, Panje C M. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review. Radiat Oncol 2020; 15:174.
   
Schmid H P, Viktorin P, Putora P M, Schiefer J, Schwab C, Plasswilm L, Engeler D S. Langzeitresultate des prospektiven Schweizer Registers LDR-Brachytherapie des lokalisierten Prostatakarzinoms. German Medical Science, www.egms.de 2020;.
   
Riesterer O, Ciernik I F, Stahel R A, Xyrafas A, Aebersold D M, Plasswilm L, Mahmut Ozsahin E, Zwahlen D R, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J, Swiss Group For Clinical Cancer Research (SAKK) . Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Radiother Oncol 2019; 138:121-125.
   
Iseli T, Plasswilm L. Radiotherapie bei schmerzhaften Metastasen: Konzept und Vorgehen in der klinischen Praxis. Schweizerische Zeitschrift für Onkologie 2019; 5:17-20.
   
Panje C, Höng L, Hayoz S, Baracos V E, Herrmann E, Garcia Schüler H, Meier U R, Henke G, Schacher S, Hawle H, Gérard M A, Ruhstaller T, Plasswilm L, Swiss Group For Clinical Cancer Research (SAKK) . Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol 2019; 14:166.
   
Plasswilm L, Studer G, Aebersold D M, Zwahlen D R. [Modern Treatment Concepts in Radiation Oncology]. Ther Umsch 2019; 76:209-218.
   
Panje C, Dedes K J, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold D M, Plasswilm L, Lupatsch J E, Swiss Group For Clinical Cancer Research (SAKK) . A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiother Oncol 2018; 129:257-263.
   
Wirsching H G, Tabatabai G, Roelcke U, Hottinger A F, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, Von Moos R, Riklin C, Felsberg J, Roth P, Jones D T W, Pfister S, Rushing E J, Abrey L, Reifenberger G, Held L, Von Deimling A, Ochsenbein A, Weller M. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol 2018; 29:1423-1430.
   
Maletzki P, Schwab C, Markart P, Engeler D S, Schiefer J, Plasswilm L, Schmid H P. Late seed migration after prostate brachytherapy with Iod-125 permanent implants. Prostate Int 2018;.
   
Panje C, Glatzer M, Sirén C, Plasswilm L, Putora P M. Treatment Options in Oncology. JCO Clin Cancer Inform 2018; 2:1-10.
   
Panje C, Glatzer M, Von Rappard J, Rothermundt C, Hundsberger T, Zumstein V, Plasswilm L, Putora P M. Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis. BMC Med Res Methodol 2017; 17:123.
   
Maletzki P, Schwab C, Markart P, Engeler D S, Schiefer J, Plasswilm L, Schmid H P. Late seed migration after prostate brachytherapy with Iod-125 permanent implants. Prostate Int 2017; 6:66-70.
   
Von Moos R, Koeberle D, Schacher S, Hayoz S, Winterhalder R C, Roth A, Bodoky G, Samaras P, Berger M D, Rauch D, Saletti P, Plasswilm L, Zwahlen D, Meier U R, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Swiss Group For Clinical Cancer Research (SAKK) . Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
   
Warschkow R, Gueller U, Cerny T, Schmied B, Plasswilm L, Putora P M. Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis. Radiother Oncol 2017; 123:139-146.
   
Putora P M, Engeler D S, Haile S, Graf N, Buchauer K, Schmid H P, Plasswilm L. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. Strahlenther Onkol 2016; 192:182-9.
   
Hundsberger T, Hottinger A F, Roelcke U, Roth P, Migliorini D, Dietrich P Y, Conen K, Pesce G, Hermann E, Pica A, Gross M W, Brügge D, Plasswilm L, Weller M, Putora P M. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neurooncol 2016; 126:175-183.
   
Glatzer M, Putora P M, Plasswilm L. Radioimmuntherapie – die neue Strategie im Kampf gegen Krebs? Wirkprinzipien, Therapiekonzepte und (prä-)klinische Studiendaten. SZO 2016;.
   
Plasswilm L, Schmid H P, Schwab C, Putora P M. (Neo-) Adjuvante endokrine Therapie des lokoregionär begrenzten Prostatakarzinoms. J Urol Urogynäkol 2015; 22:10-5.
   
Panje C, Dal Pra A, Zilli T, R Zwahlen D, Papachristofilou A, Herrera F G, Matzinger O, Plasswilm L, Putora P M. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice. Strahlenther Onkol 2015; 191:778-86.
   
Panje C, Panje T, Putora P M, Kim S K, Haile S, Aebersold D M, Plasswilm L. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. Radiat Oncol 2015; 10:47.
   
Putora P M, Engeler D S, Haile S R, Graf N, Buchauer K, Schmid H P, Plasswilm L. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. Strahlenther Onkol 2015; 192:182-9.
   
Putora P M, Ess S, Panje C, Hundsberger T, Van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis 2015; 32:143-9.
   
Engeler D S, Schwab C, Thöni A F, Hochreiter W, Prikler L, Suter S, Stucki P, Schiefer J, Plasswilm L, Schmid H P, Putora P M. PSA bounce after (125)I-brachytherapy for prostate cancer as a favorable prognosticator. Strahlenther Onkol 2015; 191:787-791.
   
Schiefer J, Ingulfsen N, Kluckert J, Peters S, Plasswilm L. Measurements of isocenter path characteristics of the gantry rotation axis with a smartphone application. Med Phys 2015; 42:1184-92.
   
Engeler D S, Schwab C, Thöni A, Hochreiter W, Prikler L, Suter S, Stucki P, Schiefer J, Plasswilm L, Schmid H P, Putora P M. PSA bounce after 125J-brachytherapy for prostate cancer as a favorable prognosticator. Strahlenther Onkol 2015; 191:787-91.
   
Maletzki P, Markart P, Engeler D S, Schiefer J, Plasswilm L, Schmid H P, Schwab C. Späte Seed-Migration nach LDR-Brachytherapie der Prostata mit J-125 Permanentimplantaten. J Urol Urogynäkol 2015; 22:4-9.
   
Schmid H P, Plasswilm L, Schiefer J. Strahlenquellen im Körper bekämpfen den Prostatakrebs. DUO 2015;14-7.
   
Schmid H P, Schiefer J, Plasswilm L. Strahlenquellen im Körper bekämpfen den Prostatakrebs. Ostschweiz am Sonntag 2015; 35:19.
   
Schwab C, Maletzki P, Markart P, Engeler D S, Schiefer J, Plasswilm L, Schmid H P. Seed-Migration nach LDR-Brachytherapie der Prostata mit Jod-125-Permanentimplantaten. J Urol Urogynäkol, 21 (Sonderheft 4):25 2014;25.
   
Putora P M, Panje C, Papachristofilou A, Pra A, Hundsberger T, Plasswilm L. Objective consensus from decision trees. Radiat Oncol 2014; 9:270.
   
Buchauer K, Henke G, Schiefer J, Plasswilm L. Surface dose characterisation of the Varian Ir-192 HDR conical surface applicator set with a vertically orientated source. Strahlenther Onkol 2014; 190:1163-8.
   
Schwab C, Maletzki P, Markart P, Engeler D S, Schiefer J, Plasswilm L, Schmid H P. Späte Seed-Migration nach LDR-Brachytherapie der Prostata mit J-125 Permanentimplantaten. Urologe, 53 (suppl 1):92 2014;92.
   
Putora P M, Plasswilm L, Seelentag W, Schiefer J, Markart P, Schmid H P, Engeler D S. Re-implantation after insufficient primary 125-I permanent prostate brachytherapy. Radiat Oncol 2013; 8:194.
   
Putora P M, Plasswilm L, Seelentag W, Schiefer J, Markart P, Schmid H P, Engeler D. Re-implantation after insufficient primary 125-i permanent prostate brachytherapy. Radiat Oncol 2013; 8:194.
   
Schwab C, Schmid H P, Plasswilm L, Engeler D S. Bounce-Phänomen als prognostisch günstiger Faktor nach LDR-Brachytherapie - prospektive Auswertung des schweizerischen Registers. Urologe 2013; 52 (suppl 1):101.
   
Putora P M, Müller J, Borovicka J, Plasswilm L, Schmidt F. Relevance of incidental colorectal FDG-PET/CT-enhanced lesions. Onkologie 2013; 36:200-4.
   
Hundsberger T, Brügge D, Putora P M, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013; 112:133-9.
   
Sassowsky M, Gut P, Hölscher T, Hildebrandt G, Müller A C, Najafi Y, Kohler G, Kranzbühler H, Guckenberger M, Zwahlen D R, Azinwi N C, Plasswilm L, Takacs I, Reuter C, Sumila M, Manser P, Ost P, Böhmer D, Pilop C, Aebersold D M, Ghadjar P. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. Int J Radiat Oncol Biol Phys 2013; 87:534-41.
   
Putora P M, Schmücking M, Aebersold D, Plasswilm L. Compensability index for compensation radiotherapy after treatment interruptions. Radiation Oncology 2012; 2012:208.
   
Preusser S, Putora P M, Plasswilm L, Schmid H P. Castration-resistant prostate cancer : Surgical and radio-oncological therapeutic options. Der Urologe 2012; 51:27-31.
   
Putora P M, Horstkemper R, Plasswilm L. Palliative Radiotherapie beim NSCLC: Indikationen und Verfahren. Schweizerische Zeitschrift für Onkologie 2012; 1:12-16.
   
Putora P M, Schmuecking M, Aebersold D, Plasswilm L. Compensability index for compensation radiotherapy after treatment interruptions. Radiat Oncol 2012; 7:208.
   
Früh M, Kacsir B, Ess S, Cerny T, Rodriguez R, Plasswilm L. Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol 2011; 187:561-7.
   
Putora P M, Paulis L, Plasswilm L. Automated Erythema Quantification in Radiation Therapy - a Java Based Tool. Applied Medical Informatics 2010; 26:1-6.
   
Putora P M, Blattner M, Papachristofilou A, Mariotti F, Paoli B, Plasswilm L. Dodes (diagnostic nodes) for Guideline Manipulation. Journal of Radiation Oncology Informatics 2010; 2:1-8.
   
Putora P M, Plasswilm L, Paulis L. Automated contrast painting for position verification in radiotherapy. Journal of Radiation Oncology Informatics 2009; 1:23-29.
   
Schiefer J, Vontoggenburg F, Seelentag W, Plasswilm L, Ries G, Lenggenhager C, Schmid H P, Leippold T, Prikler L, Krusche B, Roth J, Engeler D S. Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2009; 185:689-95.
   
Schiefer J, Vontoggenburg F, Seelentag W, Plasswilm L, Ries G, Schmid H P, Leippold T, Krusche B, Roth J, Engeler D S. Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example. Physics in medicine and biology 2009; 54:4959-70.
   
Kneifel S, Bernhardt P, Uusijärvi H, Good S, Plasswilm L, Buitrago-Téllez C, Müller-Brand J, Mäcke H, Merlo A. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas. Eur J Nucl Med Mol Imaging 2007; 34:1388-95.
   
Elicin O, Schmücking M, Bromme J, Rauch D, Ambarcioglu P, Plasswilm L, Geretschlager A, Ghadjar P, Giger R, Aebersold D M. Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis. J BUON 21:175-81.
   
Schiefer J, & Plasswilm L (2017). Temperature dependent dose error of Gafchromic EBT3 and EBT-XD film and clinical relevance in SRT. In Buchauer K (Eds.), Radiotherapy and Oncology Vol.123 (pp. 807-808): Elsevier.
   
Glatzer M, Putora P M, Müller J, Minervini F, & Plasswilm L (2016). Case report: radio-supersensitive oligometastatic lung cancer. In .
   
Schiefer J, Plasswilm L, & Henke G (2016). Vertical type surface brachytherapy applicator improvement with a 3d printed dose compensation body. In Buchauer K (Eds.), Radiotherapy and Oncology Vol.119 (pp. 954): Elsevier.
   
Buchauer K, Schiefer J, & Plasswilm L (2015). 3d printed dose compensation body to remove dose artifacts of a HDR Brachytherapy surface applicator of the vertical type. In Buchauer K (Eds.), SSRMP Annual Scientific Meeting 2015 Booklet (pp. 38): Schweizerische Gesellschaft für Strahlenbiologie und Medizinische Physik.
   
Buchauer K, Henke G, Plasswilm L, & Schiefer J (2015). The SSRMP Tomotherapy Dosimetry. In (pp. 1): -.
   
Schwab C, Thöni A, Plasswilm L, Ackermann D, Schmid H P, & Engeler D S (2014). Das Bounce-Phänomen als ein prognostisch günstiger Faktor nach interstitieller LDR-Brachytherapie mit Jod-125-Permanentimplantaten: Prospektive Auswertung des schweizerischen Registers. In (pp. 1): P1-10.
   
Buchauer K, Hoeng L, Henke G, Schiefer J, & Plasswilm L (2014). Influence of Characteristic Surface Dose on Calibration and Clinical Use of the Varian IR-192 HDR Surface Applicator Set with Vertical Leipzig-Style Cones. In Buchauer K (Eds.), (pp. 1). Lugano: 18th Annual SASRO Meeting.
   
Buchauer K, Schiefer J, & Plasswilm L (2014). Scanning protocol improvements in Gafchromic EBT-x dosimetry. In Buchauer K (Eds.), http://www.postersessiononline.eu/pr/congreso.asp?cod=336742579.
   
Abt D, Markart P, Schwab C, Engeler D S, Schiefer J, Plasswilm L, & Schmid H P (2013). Seed Migration nach LDR-Brachytherapie der Prostata mit J-125 Permanentimplantation. In (pp. 1): x.
   
Schallegger K, Brügge D, Hitz F, Hundsberger T, Cathomas R, & Plasswilm L (2012). Case Report of a patient with LGL-Leukemia who Developed a Leptomeningeal Lymphomatosis. In (pp. 128): SASRO.
   
Putora P M, Fornaro J, Devecka M, Duma M, & Plasswilm L (2012). Customized Lung Phantom for Internal Target Volume Evaluation. In (pp. 152): SASRO.
   
Naef G, Schiefer J, Peters S, Orvati C, & Plasswilm L (2012). Dosimetric Validation of Eclipse VMAT Plans for Elekta Units Using a Modified Octavius Verification Technique. In (pp. 133): SASRO.
   
Putora P M, Horstkemper R, Papachristofilou A, & Plasswilm L (2012). Manipulation and Quality Assurance of Guidelines; an Online Implementation of Diagnostic Nodes (Dodes). In (pp. 116): SASRO.
   
Horstkemper R, Putora P M, Toepfer M, & Plasswilm L (2012). Good Reponse of Palliative Radiotherapy for Very Advanced Metastastic Melanoma. In (pp. 100).
   
Buchauer K, Schiefer J, & Plasswilm L (2012). Surface dose optimization of the Varian Ir-192 HDR surface applicator set. In Buchauer K (Eds.), SSRMP Annual Scientific Meeting 2012 Proceedings & Abstracts (pp. 26): SGSMP.
   
Horstkemper R, Brügge D, Müller J, Mock B, & Plasswilm L (2012). Post Irradiation Sign of Progress in Anaplastic Ependymoma - A Case Report. In (pp. 101).
   
Putora P M, Horstkemper R, Müller J, & Plasswilm L (2012). Radiotherapy with 3Gy for Inflammation due to Heterotopic Ossifications. In (pp. 117): SASRO 2012.
   
Naef G, Brügge D, & Plasswilm L (2012). Spinal Cord Myxopapillary Ependymoma in a 15 Years Old Boy. In (pp. 112): SASRO.
   
Klass N, Klaeser B, Toepfer M, Malthaner M, Früh M, Schmidhalter D, Cihoric N, Born E, Blumstein N, Plasswilm L, Krause T, Aebersold D, & Schmuecking M (2012). Non-Gated F-18 FDG PET/CT For Target Volume Delineation in Stereotactic Body Radiation Therapy (SBRT) in Patients with Malignant Lung Lesions and Clinical Outcome. In (pp. 106): SASRO.
   
Putora P M, Brügge D, Schmidt F, Engeler D S, Müller J, & Plasswilm L (2011). Postoperative Prostate Radiotherapy: Did we need Bone Scans?. In SASRO 2011 final program (pp. 100).
   
Collon J, Schiefer J, Stolz A, Naef G, Putora P M, Schneider M, Fretz C, & Plasswilm L (2011). A Training Method for Prostate Delineation Based on CT- and MR-Images. In SASRO 2011 final program (pp. 102).
   
Brügge D, Putora P M, Engeler D S, Müller J, Schmidt F, & Plasswilm L (2011). SPECT-CT, Cholin-PET-CT, MRI and CT for Diagnosis of Prostate Cancer in the Prostate Bed, Regional Lymph Node and Bone Lesion. In SASRO 2011 final programm (pp. 99).
   
Stolz A, Schiefer J, Collon J, Naef G, Putora P M, Seelentag W, & Plasswilm L (2011). Can the Number of Cone Beam CTs be Reduced Based on the Patient Displacements Applied in the first Therapy Week?. In SASRO 2011 final program (pp. 103).
   
Putora P M, Fornaro J, Schiefer J, Brügge D, & Plasswilm L (2011). Radiotherapy Treatment Interruption Compensation Calculator for Android Based Mobile Devices. In SASRO 2011 final programm (pp. 16).
   
Brügge D, Putora P M, Hundsberger T, Weder P, Vanleyen K, & Plasswilm L (2011). Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas. In SASRO 2011 final program (pp. 101).
   
Engeler D S, Putora P M, Plasswilm L, Seelentag W, Schiefer J, & Schmid H P (2011). Reimplantation nach insuffizienter primärer I-125 LDR-Brachytherapie beim Prostatakarzinom. In Der Urologe, Supplement 1, 2011, p. 13.
   
Putora P M, Collon J, Schiefer J, Toepfer M, & Plasswilm L (2010). Automated Erythema Quantification in Radiation Therapy: Feasibility of the Development of a Custom Java Tool. In Final Program (pp. 110): SASRO.
   
Collen T, Ebert T, Warschkow R, & Plasswilm L (2010). IORT-Flab-Technique-Experience in St. Gallen. In (pp. 97): SASRO.
   
Ludwig P, Putora P M, Rogenmoser G, Plasswilm L, Baty F, & Brutsche M (2010). Factors influencing the success rates of smoking cessation intervention. In Swiss Med Wkly 2010; 140(Suppl 179) (pp. 16-17S): Editores Medicorum Helveticorum.
   
Toepfer M, Wille N, Putora P M, Brügge D, Arn M, Schiefer J, & Plasswilm L (2010). Patterns of Failure and Toxicity after Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost for Head and Neck Cancer. In Final Program SASRO 2010 (pp. 44). Bern: SASRO.
   
Putora P M, Engeler D S, Preusser S, Markart P, Vontoggenburg F, Toepfer M, Collon J, Schiefer J, Schmid H P, & Plasswilm L (2010). Erectile Function Preservation after Therapy of Localized Prostate Cancer: I125 Prostate Seed Implant Brachytherapy Versus Radical Prostatectomy. In Final Program (pp. 57): SASRO.
   
Putora P M, Schmidt F, Stolz A, Müller J, & Plasswilm L (2010). The Necessity for Workup of Incidental Colon FDG Lesions in PET-CT During Staging. In Strahlentherapie und Onkologie 2010;186 (Sondernr 1):22 (pp. 22). München: Springer / Urban&Vogel.
   
Collen T, Berger C, Seelentag W, & Plasswilm L (2010). Secondary Malignoma more than 40 Years after Irradiation of the Left Earlobe. In Final Program (pp. 95): SASRO.
   
Engeler D S, Putora P M, Plasswilm L, Seelentag W, Schiefer J, & Schmid H P (2010). Re-Implantation after Insufficient Primary 125-I Permanent Brachytherapy of Prostate Cancer. In Eur Urol Suppl 2010;9(2):205 (pp. 205): EAU.
   
Putora P M, Baty F, Ludwig P, Rogenmoser G, Plasswilm L, & Brutsche M (2010). The Influence of Malignancy and Referring Department on Smoking Cessation Success. In Journal of Thoracic Oncology 5:5 May 2010 (pp. 53): WK, LWW.
   
Naef G, Arn M, Stolz A, Schiefer J, Collon J, & Plasswilm L (2010). Three Irradiation Techniques for a Patient with Morbus Hodgkin Cancer in the Head and Thorax Regions. In Final Program (pp. 93): SASRO.
   
Putora P M, Plasswilm L, Seelentag W, Schiefer J, Schmid H P, & Engeler D S (2009). Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer. In (pp. 112): SASRO.
   
Putora P M, Plasswilm L, Seelentag W, Schiefer J, Schmid H P, & Engeler D S (2009). Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract]. In Strahlenther Onkol 185 9 (pp. 9): Springer.
   
Schiefer J, Ingulfsen N, Kluckert J, Peters S, Buchauer K, Putora P M, Henke G, & Plasswilm L (2014). Investigation of isocenter path characteristics of the gantry rotation with a smartphone application. Presented at 18th Annual SASRO meeting Lugano, Lugano.
   
Buchauer K, Schiefer J, & Plasswilm L (2013). Analyse der Oberflächendosisverteilung von Varian Ir-192 HDR Applikatoren des vertikalen Leipzig Typ. Presented at 30. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Bregenz.
   
Buchauer K, Schiefer J, & Plasswilm L (2013). Erste klinische Erfahrungen mit Tomotherapie in St. Gallen. Presented at 30. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Bregenz.
   
Putora P M, Blattner M, Paoli B, Mariotti F, Papachristofilou A, & Plasswilm L (2010). Diagnostische Knoten für die Manipulation von Leitlinien. Presented at 2. DEGRO Workshop für Klinische und Administrative Informatik in der Strahlentherapie, Freiburg im Breisgau, Deutschland.
   
 
page 1 of 1